In July 2022, KSL Beutner Laboratories launched the first indirect immunofluorescence (IIF) serum blood test to market in the United States, which positively identified laminin 332, an antigen associated with mucosal pemphigoid (MMP), a chronic and debilitating autoimmune disease.
In April 2022, KSL Diagnostics, Inc launched the first antibody test that detects an individual's immune response to COVID-19 and assesses the risk of infection if exposed. The COVID-19 Immunity Index can help monitor protection against the COVID-19 virus with a simple blood test.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5311
Published Date: Oct 12, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing prevalence of chronic disease and rise in diagnostic tests are some of the major factors anticipated to drive the growth of the immunoprotein diagnostic testing market.
The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2024-2036.
The major players in the market are of Bio-Rad Laboratories, Inc, Danaher Corporation, DiaSorin S.p.A, Enzo Biochem, Ortho Clinical Diagnostics, KSL Diagnostics Inc., KSL Beutner Laboratories, and others.
The infectious disease segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in Asia Pacific is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.